Minerva Neurosciences Announces 2M Share Offering by Selling Stockholders
Minerva Neurosciences (NASDAQ:NERV) has filed for up to 2,000,575 share offering by selling stockholders.
Neutral
or
Minerva Neurosciences News & Analysis
-
-
H.C. Wainwright maintains Minerva Neurosciences at 'neutral' with a price target of $11.00
An analyst from H.C. Wainwright maintained Minerva Neurosciences (NASDAQ: NERV) at 'neutral' with a price target of $11.00 from a prior price target of $8.00. Prior to this rating, Minerva...
-
Minerva Neurosciences earnings missed by $0.40, revenue was in line with estimates
Investing.com - Minerva Neurosciences (NASDAQ: NERV) reported second quarter EPS of $-1.120, $0.40 worse than the analyst estimate of $-0.717. Revenue for the quarter came in at $0.00 versus...
-
Minerva Neurosciences Prices $20M Offering at $10/sh
Minerva Neurosciences (NASDAQ:NERV), Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today...
-
Minerva Neurosciences earnings missed by $0.04, revenue was in line with estimates
Investing.com - Minerva Neurosciences (NASDAQ: NERV) reported first quarter EPS of $-1.310, $0.04 worse than the analyst estimate of $-1.270. Revenue for the quarter came in at $0.00 versus...
-
Minerva Neurosciences Provides Update on NDA for Roluperidone
Minerva Neurosciences (NASDAQ:NERV), Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,...
-
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences (NASDAQ:NERV), Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,...
-
Minerva Neurosciences Announces NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences (NASDAQ:NERV), Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,...
-
Minerva Neurosciences earnings missed by $0.25, revenue was inline with estimates
Investing.com - Minerva Neurosciences (NASDAQ: NERV) reported fourth quarter EPS of $-1.260, $0.25 worse than the analyst estimate of $-1.010. Revenue for the quarter came in at $0.00 versus...
-
Minerva Neurosciences Misses Q4 EPS by 25c
Minerva Neurosciences (NASDAQ:NERV) reported Q4 EPS of ($1.26), $0.25 worse than the analyst estimate of ($1.01).
-
Minerva Neurosciences Earnings beat, Revenue Inline In Q3
Investing.com - Minerva Neurosciences reported on Wednesday third quarter {{erl-103936||earnings that beat analysts' forecasts and revenue that was inline with expectations. Minerva...
-
Minerva Neurosciences Tops Q3 EPS by 9c
Minerva Neurosciences (NERV) reported Q3 EPS of ($1.29), $0.09 better than the analyst estimate of ($1.38).
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.71%
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Financials, Technology and Utilities sectors propelled shares higher. At the close in NYSE, the Dow Jones...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.07%
Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Technology, Healthcare and Telecoms sectors propelled shares higher while losses in the Financials, Oil & Gas...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.28%
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Basic Materials, Oil & Gas and Industrials sectors propelled shares lower. At the close in NYSE, the Dow...
-
Stocks - U.S. Steel Slumps, Spotify, Tesla Rise Premarket
Investing.com - Stocks in focus in premarket trading on Tuesday:• US Steel (SA:USSX34) slumped 5.6% after saying it will buy Arkansas-based Big River Steel for up to $2.3 billion by...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.13%
Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Utilities, Telecoms and Technology sectors propelled shares higher while losses in the Basic Materials, Oil...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
